210 related articles for article (PubMed ID: 36324801)
1. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
Qian G; Wang X; Patel NJ; Kawano Y; Fu X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Bade KJ; Srivatsan S; Williams ZK; Todd DJ; Weinblatt ME; Wallace ZS; Sparks JA
medRxiv; 2022 Oct; ():. PubMed ID: 36324801
[TBL] [Abstract][Full Text] [Related]
2. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study.
Qian G; Wang X; Patel NJ; Kawano Y; Fu X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Bade KJ; Srivatsan S; Williams ZK; Todd DJ; Weinblatt ME; Wallace ZS; Sparks JA
Lancet Rheumatol; 2023 Mar; 5(3):e139-e150. PubMed ID: 36844970
[TBL] [Abstract][Full Text] [Related]
3. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron.
Kawano Y; Patel NJ; Wang X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Qian G; DiIorio M; Hsu TYT; Weinblatt ME; Todd DJ; Wallace ZS; Sparks JA
medRxiv; 2022 Jun; ():. PubMed ID: 35765565
[TBL] [Abstract][Full Text] [Related]
4. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
[No Abstract] [Full Text] [Related]
5. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
6. Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases.
Gerolymatou N; Bakasis AD; Voulgari PV; Vlachoyiannopoulos PG
J Rheumatol; 2023 Aug; 50(8):1078-1081. PubMed ID: 36521909
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses following the surge of SARS-CoV-2 Omicron infection among patients with systemic autoimmune rheumatic diseases.
Xiang N; Li YJ; Liu MY; Wu QQ; Zhang YX; Jin HZ; Wang Q; Li YW; Tong DL; Xue T; Jin TC; Bao W; Chen Z
Rheumatol Adv Pract; 2023; 7(2):rkad064. PubMed ID: 37547578
[TBL] [Abstract][Full Text] [Related]
8. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
[TBL] [Abstract][Full Text] [Related]
9. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.
Kawano Y; Patel NJ; Wang X; Cook CE; Vanni KM; Kowalski EN; Banasiak EP; Qian G; DiIorio M; Hsu TY; Weinblatt ME; Todd DJ; Wallace ZS; Sparks JA
Ann Rheum Dis; 2022 Dec; 81(12):1742-1749. PubMed ID: 35944947
[TBL] [Abstract][Full Text] [Related]
10. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
[TBL] [Abstract][Full Text] [Related]
12. [Related factors of viral nucleic acid change in critically ill patients with SARS-CoV-2 infection after treatment with Nirmatrelvir/Ritonavir: a single center retrospective cohort study].
Yan M; Xie M; Zhu S; Li H; Li S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Nov; 35(11):1150-1156. PubMed ID: 37987124
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study.
Shin YH; Shin JI; Moon SY; Jin HY; Kim SY; Yang JM; Cho SH; Kim S; Lee M; Park Y; Kim MS; Won HH; Hong SH; Kronbichler A; Koyanagi A; Jacob L; Smith L; Lee KH; Suh DI; Lee SW; Yon DK
Lancet Rheumatol; 2021 Oct; 3(10):e698-e706. PubMed ID: 34179832
[TBL] [Abstract][Full Text] [Related]
15. Early Adoption of Anti-SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022.
Bajema KL; Wang XQ; Hynes DM; Rowneki M; Hickok A; Cunningham F; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Viglianti EM; Streja E; Yan L; Aslan M; Huang GD; Ioannou GN
JAMA Netw Open; 2022 Nov; 5(11):e2241434. PubMed ID: 36367727
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.
Smith DJ; Lambrou A; Patel P
MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1357-1364. PubMed ID: 38127665
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
[TBL] [Abstract][Full Text] [Related]
19. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY
J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir.
Wong GL; Yip TC; Lai MS; Wong VW; Hui DS; Lui GC
JAMA Netw Open; 2022 Dec; 5(12):e2245086. PubMed ID: 36472873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
